Hüseyin Abalı

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Hüseyin Saffet Beköz, Nuri Karadurmuş, S. Paydaş et al. · Annals of Oncology · 2017 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma

Hüseyin Abalı, Yüksel Ürün, Berna Öksüzoğlu et al. · Cancer Investigation · 2008 · 49 citations

Medicine, Oncology, Cell Therapy +12

Disclosure of Cancer Diagnosis to Patients and their Relatives in Turkey: Views of Accompanying Persons and Influential Factors in Reaching those Views

Berna Öksüzoğrlu, Hüseyin Abalı, Meral Bakar et al. · Tumori Journal · 2006 · 44 citations

Nursing, Oncology, Cancer Control +13

Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation

Umut Dişel, Serdar Öztuzcu, Ali Ayberk Beşen et al. · Lung Cancer · 2010 · 34 citations

Medicine, Molecular Genetics, Oncology +14

The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma

Nuriye Özdemir, Hüseyin Abalı, Berna Öksüzoğlu et al. · Medical Oncology · 2009 · 22 citations

Medicine, Oncology, Pharmacology +13